CD8A and graft versus host disease: Interestingly, a TCR-Vb4+CD8+ CTL targeting a novel HLA-B7-restricted MiHA, designated ZAPHIR, was isolated from RCC patient UPN686 showing partial regression of lung metastases in the absence of GVHD.